BIOCORP, a French manufacturer of medical devices and delivery systems, said on Monday that it has formed a new partnership for smart drug delivery with German science and technology company Merck KGaA (ETR:MRK).

The agreement concerns the development and supply of a specific version of Mallya device as an accessory for one of Merck's drug delivery devices. Mallya is a Bluetooth-enabled clip-on device for pen injectors that collects dose and time of each injection and transfers the data in real time to companion software.

BIOCORP and Merck intend to develop a new version of Mallya to help patients monitor their injection during their treatment. The device will automatically keep track of doses injected with timestamp and indicate that the product is administered properly, aiming to support patients with self-injections.

Financial terms of the partnership include payments from Merck of up to EUR5m for the development of the product within the first three years of the collaboration. BIOCORP estimates that additional revenues will reach up to EUR8m during the first five years after launch depending on commercial milestones and adoption of Mallya devices by Merck patients, with further upside potential in the subsequent years.